Defence Therapeutics initiate testing of ARM vaccine against pancreatic cancer
Defence Therapeutics has mandated the Transbiotech Biotechnology Research and Transfer Center to begin testing its cellular anti-cancer ARM vaccine against pancreatic cancer.
Research from the...
Defence Therapeutics’ ARM vaccine cures 100% of solid tumours in rodent models
Defence Therapeutics has revealed that the company’s cutting-edge ARM vaccine cures 100% of tumours in rodent models.
The leading biopharmaceutical company revealed that performing a...
Defence Therapeutics completes AccuTOXTM preclinical efficacy studies
Defence Therapeutics has successfully completed all essential preclinical efficacy studies for the company’s AccuTOXTM programme.
AccuTOXTM is one of Defence’s most advanced research and development...
Trademark registration approved by USPTO for DEFENCE THERAPEUTICS®
Defence Therapeutics has announced that the United States Patent and Trademark Office (USPTO) has granted registration for its trademark DEFENCE THERAPEUTICS®.
This trademark is granted...
Defence Therapeutics granted US patent for vaccine enhancer technology
Discover how the issue of a patent will allow Defence Therapeutics' vaccine enhancer technology to be commercialised.
Defence Therapeutics’ mRNA cancer vaccine testing begins
Canadian biopharmaceutical specialist Defence Therapeutics has announced that testing of its revolutionary AccumTM-linked mRNA cancer vaccine has started.
The performance of Defence’s AccumTM mRNA cancer...
Defence Therapeutics successfully develops ACCUMTM -mRNA cancer vaccine
Canadian biopharmaceutical pioneer Defence Therapeutics has revealed it has successfully conjugated mRNA molecules to AccumTM – a significant breakthrough that looks to enhance the...
Defence to perform final AccuTOXTM preclinical study before Phase I cancer trial
Defence Therapeutics has announced it is performing a final preclinical study to validate the efficacy of AccuTOXTM combined with immune-checkpoint inhibitors before initiating a...
Defence Therapeutics and Orano agree to collaborate on radio-immuno-conjugates
Defence Therapeutics Inc. is pleased to announce that they have signed a collaboration agreement with Orano to develop next-generation radio-immuno-conjugates using their intracellular targeting...
B Medical Systems donates transport boxes to Turkey and Syria
To support the relief effort in Turkey and Syria following February's earthquakes, B Medical Systems has donated 50 medical transport boxes.
B Medical Systems collaborated...
Defence advances to phase I clinical trials of the Accum technology
Defence Therapeutics Inc. is pleased to update its stakeholders on its completed achievements and outline the future milestones for AccumTM set for 2023.
Over the...
B Medical Systems’ cold chain transport box receives CERTICOL label
The CERTICOLD quality label guarantees B Medical Systems’ cold chain transport boxes RCW25 are conforming to European GDP guidelines.
B Medical Systems, a global leader...
Defence work with City of Hope in filing a new AccuTOX cancer programme
Defence Therapeutics has teamed up with City of Hope to submit an application for the clinical trialling of their AccuTOX TM technology.
The Canadian biopharmaceutical...
Defence Therapeutics begins manufacturing of it’s ARM vaccine
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the start...
Defence Therapeutics begin toxicology study on intranasal AccutoxTM
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the start...
Defence Therapeutics has melanoma vaccine validated
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the validation...
Defence Therapeutics has US patent accepted for Accum
Defence Therapeutics Inc, a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate...
Defence Therapeutics launch Accum-mRNA vaccine programme
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the advancement...
Defence’s novel Accutox intranasal reduces 50% of cancer nodules
Defence Therapeutics, a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, has just completed a pre-clinical study using...
Defence Therapeutics are using Accum technology in mRNA vaccines
Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is currently working on combining its...
